Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...

“I am pleased with our team’s continued execution across several key commercial and clinical initiatives designed to increase patient access to our life changing Zephyr Valve treatment,” said Steve ...

LONDON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Positive results from the IMPACT study demonstrate that patients with homogeneous emphysema benefit from treatment with Pulmonx Corporation’s ...

Pulmonx Corporation's shares have performed poorly over the past year, returning -16%. The company's CEO recently announced his retirement, raising questions about potential changes in corporate ...

CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, a leader in interventional pulmonology, today announced that 10,000 patients have been treated to-date with its Zephyr® Endobronchial Valve (EBV). The ...

The latest price target reset on Pulmonx brings a lower headline number, yet the fair value estimate in the model remains ...